Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3930MR)

This product GTTS-WQ3930MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3930MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12753MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ10820MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ11010MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ12823MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ50MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ12339MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ5148MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ9981MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW